CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Group 2: control group with enoxaparin 40mg/dWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1007 Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed Wiki 1.00
drug2432 TOF protocol Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial

Pragmatic randomized clinical trial of patients admitted to the hospital with confirmed COVID-19 infection and elevated D-Dimer. Randomization 1:1 - Group 1 will undergo a routine full anticoagulation (oral or parenteral when needed) strategy; and group 2 will receive usual standard of care with prophylactic anticoagulation

NCT04394377 Coronavirus Infection Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed Drug: Group 2: control group with enoxaparin 40mg/d
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: The primary objective will be analyzed using the win ratio approach comparing every participant of treatment group to every participant of control group to determine a winner.

Measure: Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.

Time: In 30 days

Secondary Outcomes

Measure: Incidence of Venous thromboembolism

Time: In 30 days

Measure: Incidence of acute myocardial infarction

Time: In 30 days

Measure: Incidence of stroke

Time: In 30 days

Measure: Number of days using oxygen therapy

Time: In 30 days

Measure: Peak of troponin

Time: In 30 days

Measure: Peak of D-dimer

Time: In 30 days

Description: It will be considered the main safety endpoint

Measure: Incidence of Major bleeding and clinically relevant non-major bleeding by the ISTH criteria

Time: In 30 days


No related HPO nodes (Using clinical trials)